Increasing airborne diseases to accelerate erdosteine market share

Posted on Updated on

The rise in air pollution owing to the increasing industrialization and urbanization along with growing smoking habits among the people has had a notable impact on erdosteine market share. Erdosteine is basically a mucolytic and has the ability to breakdown mucus which causes chronic obstructive bronchitis.

U.S. Erdosteine Market Size, By Application, 2018 & 2025, (Tons)
U.S. Erdosteine Market Size, By Application, 2018 & 2025, (Tons)

Increasing content of fumes, vapors, dust, tobacco smoke in the atmosphere damages lungs and airway tissues after exposure to these substances. Taking into account the severity associated with such chronic diseases, many health organizations, pharmaceutical companies, and medical research institutes have been involved in technological innovation that will enhance erdosteine industry outlook over the coming years.

In the last few years, air pollution level has increased tremendously worldwide and has proved to be severely dangerous to human health. As per the World Health Organization (WHO) in 2018, around 9 out of 10 people breathe air that contains high-level air pollutants. It further claimed that every year nearly 7 million people are estimated to lose their lives annually due to household and ambient air pollution. More than 40% population of the world does not get clean cooking technologies and fuel in their homes – leading to household air pollution. This will further increase erdosteine demand in the years to come.

In the low and middle-income countries across Africa and Asia, over 90% deaths occur due to air-pollution related diseases. Since the last few decades, WHO has been monitoring air pollution levels across sub-Saharan Africa to tabulate the data regarding the use of technologies to curb air pollution. In this regard, growing awareness among the regional governments about the need for sustainable development is likely to strengthen erdosteine market size.

Get a Sample Copy of this Report:

In line with the air pollution control activities, the ongoing development of mucus regulating medicines across the globe will further generate lucrative business opportunities for the players in erdosteine industry. The consistent development of drug formulas to treat diseases caused by air contamination will drive the erdosteine market share over the coming years.

Surging pollution levels and increasing tobacco smoke are the two major concerns troubling the U.S. federal government. In order to target these concerns, the U.S. government has been striving to implement strict regulatory policies through organizations like FDA. The laws are framed to ensure fairness between health-regulated sectors and safeguard public health. Aided by a supportive regulatory spectrum, pharmaceutical companies have been introducing cost-effective and efficient medicines in the market. Proliferating availability of flexible and affordable medicines is slated to impel U.S. erdosteine industry trends.

Recently, WHO found that the tobacco epidemic is one of the largest public health threats causing the death of over 8 million people every year. Out of those, nearly 7 million deaths are the result of direct consumption of tobacco and 1.2 million deaths are the result of passive or non-direct smoking. Across the globe, only 37 countries, that account for 15% of the world’s population have completely banned all forms of promotion, advertising, and sponsorship for tobacco. High tobacco taxes and growing demand for cigarettes and tobacco products have thus been augmenting erdosteine market size.

Over the last few years, due to an outburst of airway and systemic inflammation cases, several research organizations have been working to evaluate the usage of erdosteine in exacerbations of COPD. They have been also focusing on the development of highly effective medicines causing low-side effects to the patients. Thus, growing demand for medicines with high clinical benefits and lesser aftereffect will further enhance erdosteine industry outlook.

Taking into account the growing involvement of biggies in new product development along with increasing awareness among the people about active medication, Global Market Insights, Inc., estimates that by the end of 2025, worldwide erdosteine market will generate a revenue of more than USD 150 million.

The increasing importance of erdosteine for preventing recurrence of exacerbation of COPD patients will accelerate the product demand over the years ahead. Alarming level of air pollution and its hazardous impact on the living organisms across the globe will create new opportunities for the pharmaceutical companies including Alitair Pharmaceuticals, Taj Pharmaceuticals, Hanmi Pharmaceuticals, and Delta Finochem.

Author NameSunil Hebbalkar


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s